Slide 1: First Quarter 2021 Financial Results & Business Update
First Quarter 2021 Financial Results & Business Update April 28, 2021 Exhibit 99.2
Slide 2: Forward-Looking Statements and Non-GAAP Financial Information
Forward-Looking Statements and Non-GAAP Financial Information Certain statements set forth in this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: the co
Slide 3: Agenda
Agenda Introduction Sandy Coombs, SVP, Corporate Affairs & Investor Relations Corporate Update Richard Pops, Chief Executive Officer Q1 2021 Financial Results Iain Brown, Chief Financial Officer Q1 2021 Commercial Review Todd Nichols, Chief Commercial Officer R&D Pipeline Update Richard Pops, Chief
Slide 4: Q1 2021 Financial Results Summary
Q1 2021 Financial Results Summary In millions In millions In millions
Slide 5: First Quarter 2021 Revenue Summary
First Quarter 2021 Revenue Summary Amounts in the table above do not sum due to rounding. *Decrease in VIVITROL net sales in Q1’21 was primarily due to COVID-19 pandemic-related disruptions. ** Inclusive of ARISTADA INITIO®
Slide 6: Alkermes: 2021 Financial Expectations
Alkermes: 2021 Financial Expectations†* † These expectations were initially provided by Alkermes plc (the “Company”) in its Current Report on Form 8-K filed with the SEC on Feb. 11, 2021. These expectations are reiterated by the Company in its Current Report on Form 8-K filed with the SEC on April 2
Slide 7: Disciplined Capital Allocation Supports Highest ROI Priorities
Disciplined Capital Allocation Supports Highest ROI Priorities Drive operating margins of commercial business and focus on profitability Create value through innovation and position ALKS for future growth
Slide 8: VIVITROL Performance and Expectations
VIVITROL® Performance and Expectations Q1’21 year-over-year net sales declined 5% to $74.5M, driven by unit decline of 6% Gross-to-net deductions: 51.5% in Q1’21, compared to 50.6% in Q4’20, and an average of 49.9% in 2020 Inventory levels decreased by approximately $2.3M from Q4’20 FY’21 net sales
Slide 9: ARISTADA Performance and Expectations
ARISTADA® Performance and Expectations Q1’21 year-over-year net sales growth of 9% to $55.4M, driven by unit growth of 6% Gross-to-net deductions: 53.3% in Q1’21, compared to 54.1% in Q4’20 Inventory levels decreased by approximately $8.0M from Q4’20 FY’21 net sales expected to range from $260M - $2
Slide 10: ARISTADA: Prescription Growth Trends
ARISTADA®: Prescription Growth Trends Q1 year-over-year growth of 11% on TRx months of therapy (MOT) basis Outpaced overall atypical long-acting injectable (LAI) market Q1 year-over-year growth of 3% Market share: TRx MOT: 9.2% of atypical LAI market prescriptions in Q1‘21 ARISTADA Quarterly TRx MOT
Slide 11: Nemvaleukin Alfa Development Program Progress
Nemvaleukin Alfa Development Program Progress Mucosal melanoma Nemvaleukin granted Orphan Drug Designation by U.S. Food and Drug Administration Initiated ARTISTRY-6 phase 2 monotherapy study of nemvaleukin Platinum-resistant ovarian cancer Entered clinical trial collaboration and supply agreement wi
Slide 12: Focus and Discipline Integral to R&D Portfolio Advancement
Focus and Discipline Integral to R&D Portfolio Advancement Discovery Phase Phase 1 Phase 2 Phase 3 Preclinical Phase Oncology Neuroscience
Slide 13: www.alkermes.com
www.alkermes.com